Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease

Abrams RMC, Elder GA (2018) Safety of therapeutic plasma exchange for the treatment of Guillain-Barre syndrome in polycythemia vera. Neurologist. 23(6):185–187

Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 75:2950–2973

Fehrenbacher JC (2015) Chemotherapy-induced peripheral neuropathy. Prog Mol Biol Transl Sci 131:471–508

Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC (2014) Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain. 137(Pt 1):33–43

Guidon AC, Amato AA (2020) COVID-19 and neuromuscular disorders. Neurology. 94:959–969

Gutierrez-Ortiz C, Mendez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Manas R et al (2020) Miller fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. https://doi.org/10.1212/WNL.0000000000009619

James J, Jose J (2017) Syndrome of inappropriate secretion of antidiuretic hormone preceding Guillain-Barre syndrome. J Clin Diagn Res 11(9):OD16–OD17

Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, Roodbol J, Hoogenboezem T, Jacobs E, van Rijn M, van der Eijk AA, Vink C, de Wit MCY, van Rossum AMC, Jacobs BC (2016) Mycoplasma pneumoniae triggering the Guillain-Barre syndrome: a case-control study. Ann Neurol 80(4):566–580

Padroni M, Mastrangelo V, Asioli GM, Pavolucci L, Abu-Rumeileh S, Piscaglia MG et al (2020) Guillain-Barre syndrome following COVID-19: new infection, old complication? J Neurol 267(7):1877–1879

Sedaghat Z, Karimi N (2020) Guillain Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci 76:233–235

Steinberger BA, Ford SM, Coleman TA (2003) Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia. Am J Hematol 73(2):97–100

Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA (2020) Hematological findings and complications of COVID-19. Am J Hematol 95:834–847

Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, Franciotta D, Baldanti F, Daturi R, Postorino P, Cavallini A, Micieli G (2020) Guillain-Barre syndrome associated with SARS-CoV-2. N Engl J Med 382:2574–2576

Wijdicks EF, Klein CJ (2017) Guillain-Barre syndrome. Mayo Clin Proc 92(3):467–479

Zhao Q, He Y (2020) Challenges of convalescent plasma therapy on COVID-19. J Clin Virol 127:104358

Zhao H, Shen D, Zhou H, Liu J, Chen S (2020) Guillain-Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 19(5):383–384